418 related articles for article (PubMed ID: 34035226)
1. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response.
Wang Y; Liang Y; Xu H; Zhang X; Mao T; Cui J; Yao J; Wang Y; Jiao F; Xiao X; Hu J; Xia Q; Zhang X; Wang X; Sun Y; Fu D; Shen L; Xu X; Xue J; Wang L
Cell Discov; 2021 May; 7(1):36. PubMed ID: 34035226
[TBL] [Abstract][Full Text] [Related]
2. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.
Stouten I; van Montfoort N; Hawinkels LJAC
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052
[TBL] [Abstract][Full Text] [Related]
3. PLA2G2A
Ge W; Yue M; Lin R; Zhou T; Xu H; Wang Y; Mao T; Li S; Wu X; Zhang X; Wang Y; Ma J; Wang Y; Xue S; Shentu D; Cui J; Wang L
Cancer Lett; 2023 Apr; 558():216095. PubMed ID: 36796670
[TBL] [Abstract][Full Text] [Related]
4. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
Yu Y; Schuck K; Friess H; Kong B
Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
[TBL] [Abstract][Full Text] [Related]
5. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of Cancer-Associated Fibroblasts and the Tumor Immune Microenvironment in Pancreatic Cancer.
Shinkawa T; Ohuchida K; Nakamura M
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010986
[TBL] [Abstract][Full Text] [Related]
7. Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma.
Neuzillet C; Nicolle R; Raffenne J; Tijeras-Raballand A; Brunel A; Astorgues-Xerri L; Vacher S; Arbateraz F; Fanjul M; Hilmi M; Samain R; Klein C; Perraud A; Rebours V; Mathonnet M; Bièche I; Kocher H; Cros J; Bousquet C
J Pathol; 2022 Dec; 258(4):408-425. PubMed ID: 36102377
[TBL] [Abstract][Full Text] [Related]
8. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
9. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway.
Zheng S; Hu C; Lin H; Li G; Xia R; Zhang X; Su D; Li Z; Zhou Q; Chen R
J Exp Clin Cancer Res; 2022 Feb; 41(1):71. PubMed ID: 35189958
[TBL] [Abstract][Full Text] [Related]
10. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer.
McAndrews KM; Chen Y; Darpolor JK; Zheng X; Yang S; Carstens JL; Li B; Wang H; Miyake T; Correa de Sampaio P; Kirtley ML; Natale M; Wu CC; Sugimoto H; LeBleu VS; Kalluri R
Cancer Discov; 2022 Jun; 12(6):1580-1597. PubMed ID: 35348629
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment.
Boyd LNC; Andini KD; Peters GJ; Kazemier G; Giovannetti E
Semin Cancer Biol; 2022 Jul; 82():184-196. PubMed ID: 33737108
[TBL] [Abstract][Full Text] [Related]
12. The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities.
Masugi Y
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805064
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology.
Feldmann K; Maurer C; Peschke K; Teller S; Schuck K; Steiger K; Engleitner T; Öllinger R; Nomura A; Wirges N; Papargyriou A; Jahan Sarker RS; Ranjan RA; Dantes Z; Weichert W; Rustgi AK; Schmid RM; Rad R; Schneider G; Saur D; Reichert M
Gastroenterology; 2021 Jan; 160(1):346-361.e24. PubMed ID: 33007300
[TBL] [Abstract][Full Text] [Related]
14. Fibroblasts in pancreatic cancer: molecular and clinical perspectives.
Rebelo R; Xavier CPR; Giovannetti E; Vasconcelos MH
Trends Mol Med; 2023 Jun; 29(6):439-453. PubMed ID: 37100646
[TBL] [Abstract][Full Text] [Related]
15. Subpopulations of cancer-associated fibroblasts link the prognosis and metabolic features of pancreatic ductal adenocarcinoma.
Hu B; Wu C; Mao H; Gu H; Dong H; Yan J; Qi Z; Yuan L; Dong Q; Long J
Ann Transl Med; 2022 Mar; 10(5):262. PubMed ID: 35402584
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy.
Luong T; Golivi Y; Nagaraju GP; El-Rayes BF
Cytokine Growth Factor Rev; 2022 Dec; 68():107-115. PubMed ID: 36096869
[TBL] [Abstract][Full Text] [Related]
17. The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis.
Barrera LN; Ridley PM; Bermejo-Rodriguez C; Costello E; Perez-Mancera PA
J Physiol Biochem; 2023 Feb; 79(1):193-204. PubMed ID: 35767180
[TBL] [Abstract][Full Text] [Related]
18. Multiphasic Heterogeneity of Fibroblasts in the Microenvironment of Pancreatic Ductal Adenocarcinoma: Dissection and the Sum of the Dynamics.
Ijichi H
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230803
[TBL] [Abstract][Full Text] [Related]
19. GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells.
Wiley SZ; Sriram K; Liang W; Chang SE; French R; McCann T; Sicklick J; Nishihara H; Lowy AM; Insel PA
FASEB J; 2018 Mar; 32(3):1170-1183. PubMed ID: 29092903
[TBL] [Abstract][Full Text] [Related]
20. Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer.
Bryce AS; Dreyer SB; Froeling FEM; Chang DK
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
